

# Paolo Gionchetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145381/publications.pdf>

Version: 2024-02-01

206  
papers

21,232  
citations

15466

65  
h-index

9839

141  
g-index

210  
all docs

210  
docs citations

210  
times ranked

13783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 76-84.	0.9	6
2	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
3	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
4	New endoscopic capsule vs upper gastrointestinal endoscopy in preoperative work-up of obese candidate for bariatric surgery: Relevance of a pilot study in the COVID-19 era. <i>Endoscopy International Open</i> , 2022, 10, E183-E191.	0.9	0
5	PANENTERIC CAPSULE ENDOSCOPY TO CHARACTERIZE CROHN'S DISEASE PHENOTYPES AND PREDICT CLINICAL OUTCOMES IN CHILDREN AND ADULTS. <i>Gastrointestinal Endoscopy</i> , 2022, 95, AB429.	0.5	0
6	Long term remission after ileorectal anastomosis in Crohn's colitis. <i>Digestive and Liver Disease</i> , 2021, 53, 592-597.	0.4	4
7	COVID-19 in IBD: The experience of a single tertiary IBD center. <i>Digestive and Liver Disease</i> , 2021, 53, 271-276.	0.4	32
8	Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	0
9	Pouchitis: Clinical Features, Diagnosis, and Treatment. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3871-3879.	0.8	11
10	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
11	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	1.9	13
12	Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 321-330.	0.9	38
13	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
14	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
15	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020, 52, 506-515.	0.4	14
16	Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn's Disease. <i>Crohn's &amp; Colitis</i> 360, 2020, 2, .	0.5	7
17	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	1.4	11
18	Usefulness of panoramic 344°-viewing in Crohn's disease capsule endoscopy: a proof of concept pilot study with the novel PillCam, Crohn's system. <i>BMC Gastroenterology</i> , 2020, 20, 97.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Strictureplasty for Crohn's disease of the small bowel in the biologic era: long-term outcomes and risk factors for recurrence. <i>Techniques in Coloproctology</i> , 2020, 24, 711-720.	0.8	7
20	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	0.8	19
21	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	0.7	12
22	Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 607-613.	1.4	9
23	Implications of the Westernized Diet in the Onset and Progression of IBD. <i>Nutrients</i> , 2019, 11, 1033.	1.7	142
24	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 613-620.	0.4	14
25	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
26	Predictors of early recurrence after strictureplasty for Crohn's disease of the small bowel during the years of biologics. <i>Digestive and Liver Disease</i> , 2019, 51, 663-668.	0.4	9
27	A current overview of corticosteroid use in active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 557-561.	1.4	37
28	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	1.1	27
29	Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?. <i>Updates in Surgery Series</i> , 2019, , 93-104.	0.0	0
30	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	1.3	16
31	Transabdominal salvage surgery after pouch failure in a tertiary center: A case-matched study. <i>Digestive and Liver Disease</i> , 2018, 50, 446-451.	0.4	9
32	Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 273-279.	0.6	24
33	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018, 50, 653-660.	0.4	22
34	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018, 36, 346-353.	0.8	1
35	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	0.5	29
36	The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 963-969.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
38	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.4	47
39	Probiotics, Prebiotics, and Antibiotics in IBD. , 2017, , 455-469.		1
40	Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis. <i>Journal of Rheumatology</i> , 2017, 44, 1341-1346.	1.0	15
41	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 649-670.	0.6	1,324
42	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.4	13
43	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	0.6	1,547
44	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	0.6	558
45	Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. <i>Journal of Ultrasound</i> , 2017, 20, 273-284.	0.7	26
46	Risks and Benefits of Mucosal Healing With Combined Immunosuppression in Paediatric Crohn's Disease: A Complex Topic That Needs Careful Evaluation. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jiw220.	0.6	0
47	Can supplementation of phytoestrogens/insoluble fibers help the management of duodenal polyps in familial adenomatous polyposis?. <i>Carcinogenesis</i> , 2016, 37, 600-606.	1.3	8
48	European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jiw188.	0.6	79
49	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.4	34
50	IBD and spondyloarthritis: joint management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 9-10.	8.2	13
51	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	0.6	251
52	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 4-25.	0.6	285
53	The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1175-1181.	1.4	19
54	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	2.4	181

#	ARTICLE	IF	CITATIONS
55	Absence of change in the gray matter volume of patients with ulcerative colitis in remission: a voxel based morphometry study. <i>BioPsychoSocial Medicine</i> , 2015, 9, 1.	0.9	20
56	Inflammatory Bowel Diseases and Spondyloarthropathies. <i>Journal of rheumatology Supplement</i> , The, 2015, 93, 21-23.	2.2	31
57	Sporadic small bowel tumors detected by capsule endoscopy in patients with occult gastrointestinal bleeding. <i>Internal and Emergency Medicine</i> , 2015, 10, 781-785.	1.0	4
58	Attachment and quality of life in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2014, 29, 1291-1296.	1.0	31
59	The role of Budesonide-MMX in active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 215-222.	1.4	9
60	Mucosal healing in pediatric Crohn's disease after anti-TNF therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 458-465.	0.8	36
61	Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease. <i>Pathology</i> , 2014, 46, 439-443.	0.3	4
62	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	0.6	53
63	A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1485-1493.e2.	2.4	256
64	Oral beclomethasone dipropionate in chronic refractory pouchitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 649-653.	0.6	37
65	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.4	39
66	Sequential rescue therapy in steroid-refractory ulcerative colitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 521-523.	8.2	5
67	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	2.5	84
68	Systems Biology Approaches for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2104-2114.	0.9	32
69	Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. <i>Journal of Behavioral Medicine</i> , 2013, 36, 477-487.	1.1	51
70	Four cases of carcinoid tumour in Crohn's disease: coincidence or correlation?. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1743-1745.	1.0	5
71	Obscure gastrointestinal bleeding: single centre experience of capsule endoscopy. <i>Internal and Emergency Medicine</i> , 2013, 8, 681-687.	1.0	20
72	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422

#	ARTICLE	IF	CITATIONS
73	Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 675-685.	1.7	21
74	New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. <i>Neurogastroenterology and Motility</i> , 2013, 25, 147.	1.6	87
75	The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 501-512.	1.9	152
76	Adalimumab in active ulcerative colitis: A real-life observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.4	72
77	Risk of permanent stoma in extensive Crohn's colitis: the impact of biological drugs. <i>Colorectal Disease</i> , 2013, 15, 1115-1122.	0.7	37
78	Rescue therapy: ciclosporin or infliximab?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 503-505.	1.3	1
79	News and controversy in inflammatory bowel disease treatment. <i>Italian Journal of Medicine</i> , 2013, , 179-186.	0.2	0
80	Clinical management of severe active ulcerative colitis in the TNF- $\alpha$ inhibitors era. <i>Italian Journal of Medicine</i> , 2013, 7, 272.	0.2	0
81	Eviendep <sup>®</sup> reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. <i>World Journal of Gastroenterology</i> , 2013, 19, 5671.	1.4	18
82	Management and treatment of distal ulcerative colitis. <i>Italian Journal of Medicine</i> , 2013, 7, 265.	0.2	0
83	Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2012, 142, 473-481.e4.	0.6	165
84	Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease. , 2012, , 517-534.		1
85	The role of antibiotics and probiotics in pouchitis. <i>Annals of Gastroenterology</i> , 2012, 25, 100-105.	0.4	22
86	Author's reply. <i>Annals of Gastroenterology</i> , 2012, 25, 371.	0.4	0
87	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	2.4	316
88	Clinical course of microscopic colitis in a single-center cohort study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 218-221.	0.6	19
89	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease†. <i>Digestive and Liver Disease</i> , 2011, 43, 1-20.	0.4	125
90	Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 724-734.	1.9	146

#	ARTICLE	IF	CITATIONS
91	Distinct proteomic profiles characterise non-erosive from erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 982-993.	1.9	5
92	Brain functional changes in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1769-1777.	0.9	65
93	Role of conventional therapies in the era of biological treatment in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 1797.	1.4	11
94	Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 4496.	1.4	0
95	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1180-1186.	0.9	86
96	Local Injection of Adalimumab for Perianal Crohn's Disease: Better Than Infliximab?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1631.	0.9	29
97	Potential role of the cannabinoid receptor CB <sub>1</sub> in the pathogenesis of erosive and non-erosive gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 603-611.	1.9	9
98	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 63-101.	0.6	695
99	Adalimumab in a patient with steroid-dependent Crohn's disease. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 38-39.	0.2	0
100	Parental Bonding and Inflammatory Bowel Disease. <i>Psychosomatics</i> , 2010, 51, 14-21.	2.5	27
101	Parental Bonding and Inflammatory Bowel Disease. <i>Psychosomatics</i> , 2010, 51, 14-21.	2.5	22
102	Adult Attachment and Early Parental Experiences in Patients With Crohn's Disease. <i>Psychosomatics</i> , 2010, 51, 208-215.	2.5	34
103	Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. <i>World Journal of Gastroenterology</i> , 2010, 16, 30-41.	1.4	12
104	Parvovirus B19 Infection Localized in the Intestinal Mucosa and Associated with Severe Inflammatory Bowel Disease. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1591-1595.	1.8	20
105	Implications of antioxidant enzymes in human gastric neoplasms. <i>International Journal of Molecular Medicine</i> , 2009, 24, 693-700.	1.8	27
106	Clinical guidelines for the management of pouchitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1424-1431.	0.9	111
107	Immunoregulatory activity of rifaximin associated with a resistant mutant of <i>Bifidobacterium infantis</i> . <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 387-389.	1.1	7
108	Attualità e controversie nella terapia delle malattie infiammatorie croniche intestinali. <i>Italian Journal of Medicine</i> , 2009, 3, 179-186.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Pouchitis. , 2009, , 195-205.		0
110	Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 759-764.	1.9	97
111	Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 250-255.	1.9	13
112	Interaction of probiotic <i>Lactobacillus</i> and <i>Bifidobacterium</i> strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production. <i>International Journal of Food Microbiology</i> , 2008, 125, 286-292.	2.1	344
113	European evidence-based Consensus on the management of ulcerative colitis: Special situations. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 63-92.	0.6	206
114	Corrigendum to "European evidence-based consensus on the management of ulcerative colitis: Special situations" [ <i>J Crohn's &amp; Colitis</i> 2 (2008) 63-92]. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 191.	0.6	1
115	Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy. <i>Dermatology</i> , 2007, 215, 295-300.	0.9	49
116	Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. <i>European Journal of Radiology</i> , 2007, 62, 114-121.	1.2	125
117	Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2007, 133, 808-817.	0.6	87
118	Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. <i>Digestive and Liver Disease</i> , 2007, 39, 329-337.	0.4	51
119	Potential role for the common cystic fibrosis ΔF508 mutation in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 531-536.	0.9	23
120	Oral budesonide in the treatment of chronic refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1231-1236.	1.9	129
121	Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1311-1316.	1.9	35
122	Pre-pouch ileitis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 964-964.	1.9	0
123	Sympathetic hyperactivity in patients with ulcerative colitis. <i>Clinical Autonomic Research</i> , 2007, 17, 217-220.	1.4	22
124	High-Dose Probiotics for the Treatment of Active Pouchitis. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 2075-2084.	0.7	179
125	Infliximab in the treatment of Crohn's disease. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 301-308.	0.9	32
126	Increased risk of breast cancer in first-degree relatives of Crohn's disease patientsAn IG-IBD study. <i>Digestive and Liver Disease</i> , 2006, 38, 18-23.	0.4	19



#	ARTICLE	IF	CITATIONS
127	Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World Journal of Gastroenterology, 2006, 12, 5987.	1.4	47
128	Antibiotics and probiotics in treatment of inflammatory bowel disease. World Journal of Gastroenterology, 2006, 12, 3306.	1.4	122
129	CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Techniques in Coloproctology, 2006, 10, 99-105.	0.8	55
130	Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut, 2006, 55, 833-841.	6.1	211
131	Antimicrobials in the Management of Inflammatory Bowel Disease. Digestion, 2006, 73, 77-85.	1.2	68
132	Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World Journal of Gastroenterology, 2006, 12, 5978.	1.4	104
133	Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine. Journal of Clinical Gastroenterology, 2005, 39, 291-297.	1.1	59
134	Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Alimentary Pharmacology and Therapeutics, 2005, 21, 881-887.	1.9	51
135	Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin-1 $\beta$ , Interleukin-8, and Interferon- $\gamma$ Gene Expression. Inflammatory Bowel Diseases, 2005, 11, 447-454.	0.9	61
136	Local Injection of Infliximab for the Treatment of Perianal Crohn's Disease. Diseases of the Colon and Rectum, 2005, 48, 768-774.	0.7	96
137	Probiotic Therapy to Prevent Pouchitis Onset. Diseases of the Colon and Rectum, 2005, 48, 1493.	0.7	9
138	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. American Journal of Gastroenterology, 2005, 100, 84-92.	0.2	116
139	Management of Inflammatory Bowel Disease: Does Rifaximin Offer Any Promise?. Chemotherapy, 2005, 51, 96-102.	0.8	20
140	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. American Journal of Gastroenterology, 2005, 100, 1539-1546.	0.2	659
141	VSL#3: An Analysis of Basic and Clinical Contributions in Probiotic Therapeutics. Gastroenterology Clinics of North America, 2005, 34, 499-513.	1.0	30
142	Probiotics and barrier function in colitis. Gut, 2005, 54, 898-900.	6.1	21
143	Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004, 53, 108-114.	6.1	783
144	Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut, 2004, 53, 1602-1609.	6.1	483

#	ARTICLE	IF	CITATIONS
145	CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. <i>International Journal of Colorectal Disease</i> , 2004, 19, 165-170.	1.0	18
146	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. <i>Digestive and Liver Disease</i> , 2004, 36, 121-124.	0.4	31
147	Management of pouch dysfunction or pouchitis with an ileoanal pouch. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 993-1006.	1.0	12
148	Diagnosis and treatment of pouchitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 75-87.	1.0	37
149	The effect of transient intestinal ischemia on inflammatory parameters. <i>International Journal of Colorectal Disease</i> , 2003, 18, 78-85.	1.0	24
150	Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. <i>FEMS Immunology and Medical Microbiology</i> , 2003, 38, 165-172.	2.7	241
151	Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1471-1480.	1.9	94
152	Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. <i>Clinical and Experimental Immunology</i> , 2003, 132, 473-476.	1.1	84
153	Probiotics for the treatment of postoperative complications following intestinal surgery. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 821-831.	1.0	41
154	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, A377.	0.6	28
155	Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. <i>Gastroenterology</i> , 2003, 124, 1202-1209.	0.6	1,048
156	Standard Treatment of Ulcerative Colitis. <i>Digestive Diseases</i> , 2003, 21, 157-167.	0.8	37
157	Prophylaxis of pouchitis onset with probiotic therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 835.	0.8	10
158	Probiotics in gastroenterology. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 235-239.	1.0	15
159	Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 909-917.	1.9	185
160	Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1109-1116.	1.9	119
161	Variable Response to Probiotics in Two Models of Experimental Colitis in Rats. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 399-406.	0.9	115
162	Ileal pouchitis-related arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 32, 204-205.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Efficacy of a symbiotic preparation on functional intestinal disorders (FD) with altered bowel habit: A double-blind controlled study. <i>Gastroenterology</i> , 2001, 120, A750-A751.	0.6	1
164	Probiotics and antibiotics in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 331-335.	1.0	25
165	Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 251-256.	1.9	79
166	Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. <i>Clinical and Experimental Immunology</i> , 2001, 123, 395-401.	1.1	26
167	Bacteria as the cause of ulcerative colitis. <i>Gut</i> , 2001, 48, 132-135.	6.1	169
168	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. <i>American Journal of Gastroenterology</i> , 2001, 96, 2691-2699.	0.2	193
169	Role of probiotics in inflammatory bowel disease and intestinal infections. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1277-1283.	2.4	1
170	Probiotics in infective diarrhoea and inflammatory bowel diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 489-493.	1.4	114
171	MCP-3 in inflammatory bowel disease Reply. <i>Gut</i> , 2000, 47, 155-155.	6.1	2
172	Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. <i>Gastroenterology</i> , 2000, 119, 305-309.	0.6	1,373
173	Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo controlled trial. <i>Gastroenterology</i> , 2000, 118, A190.	0.6	26
174	A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 381-388.	1.9	57
175	Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 713-718.	1.9	214
176	Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1103-1108.	1.9	485
177	Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus "A GISC study. <i>European Journal of Human Genetics</i> , 1999, 7, 567-573.	1.4	81
178	Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1220-1221.	1.1	135
179	Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?. <i>Gastroenterology</i> , 1999, 116, 1246-1249.	0.6	188
180	Relapsing ulcerative colitis after spinal cord stimulation: A case of intestinal neurogenic inflammation?. <i>Gastroenterology</i> , 1999, 117, 1256-1257.	0.6	9

#	ARTICLE	IF	CITATIONS
181	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor- $\alpha$ in ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2923-2928.	0.2	74
182	Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis. <i>American Journal of Pathology</i> , 1999, 155, 331-336.	1.9	259
183	Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 93-97.	0.7	127
184	Rifaximin systemic absorption in patients with ulcerative colitis. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 91-93.	0.8	38
185	Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 361-366.	1.9	52
186	Recognition of Bactericidal/Permeability-Increasing Protein by Perinuclear Anti-Neutrophil Cytoplasmic Antibody-Positive Sera from Ulcerative Colitis Patients: Prevalence and Clinical Significance. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1284-1288.	0.6	17
187	Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. <i>Digestive Diseases and Sciences</i> , 1997, 42, 2606-2611.	1.1	19
188	Medical treatment of ulcerative colitis. <i>Current Opinion in Gastroenterology</i> , 1996, 12, 352-355.	1.0	3
189	Prediction of relapse in patients with Crohn's disease in remission. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 955-962.	0.8	30
190	Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2589-2594.	1.1	61
191	Mucosal concentrations of interleukin-1 $\beta$ , interleukin-6, interleukin-8, and tumor necrosis factor- $\alpha$ in pelvic ileal pouches. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1525-1531.	1.1	69
192	Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. <i>Digestive Diseases and Sciences</i> , 1994, 39, 550-554.	1.1	13
193	p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. <i>Lancet, The</i> , 1994, 344, 886-887.	6.3	64
194	Macrophage subpopulations and interleukin-1 $\beta$ tissue levels in pelvic ileal pouches. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 217-222.	0.8	3
195	Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 125-130.	0.8	55
196	Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of x-ray-demonstrated lesions of crohn's disease. <i>Digestive Diseases and Sciences</i> , 1993, 38, 433-437.	1.1	37
197	Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease.. <i>Gut</i> , 1993, 34, 1289-1290.	6.1	7
198	Clinical management of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 1993, 9, 571-581.	1.0	1

#	ARTICLE	IF	CITATIONS
199	Changes in Splanchnic Hemodynamics in Inflammatory Bowel Disease Non-Invasive Assessment by Doppler Ultrasound Flowmetry. Scandinavian Journal of Gastroenterology, 1992, 27, 501-507.	0.6	90
200	Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Digestive Diseases and Sciences, 1992, 37, 1890-1897.	1.1	88
201	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Digestive Diseases and Sciences, 1992, 37, 29-32.	1.1	70
202	Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Digestive Diseases and Sciences, 1991, 36, 174-178.	1.1	65
203	Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.. Gut, 1991, 32, 929-931.	6.1	105
204	Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. International Journal of Colorectal Disease, 1990, 5, 79-81.	1.0	52
205	5-Aminosalicylic acid suppositories in the management of ulcerative colitis. Diseases of the Colon and Rectum, 1989, 32, 398-399.	0.7	15
206	Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Diseases of the Colon and Rectum, 1986, 29, 108-110.	0.7	45